# Low-Dose Danazol for the Treatment of Telomere Related Diseases

> **NCT03312400** · PHASE2 · RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 40 (estimated)

## Conditions studied

- Telomere Disease

## Interventions

- **DRUG:** Danazol

## Key facts

- **NCT ID:** NCT03312400
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-02-08
- **Primary completion:** 2027-04-29
- **Final completion:** 2027-10-29
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312400, "Low-Dose Danazol for the Treatment of Telomere Related Diseases". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03312400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*